bintrafusp alfa
Recombinant proteinexperimental
Clinical trial activity
54 trials · 36 clinical orgs · 0 marketing orgs
Phase 1
29
Phase 2
41
Phase 3
2
Phase 4
0
Earliest trial started Feb 27, 2018 (NCT03427411)
Timeline
Indications
Studied for
- Alphapapillomavirus · Phase 1/Phase 2
- Anus Neoplasms · Phase 2
- Biliary Tract Neoplasms · Phase 2/Phase 3
- Brain Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Small Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Cholangiocarcinoma · Phase 2/Phase 3
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 2
- Esthesioneuroblastoma, Olfactory · Phase 2
- Gallbladder Neoplasms · Phase 2/Phase 3
- Head and Neck Neoplasms · Phase 1/Phase 2
- Human papillomavirus 16 · Phase 1/Phase 2
- Laryngeal Neoplasms · Phase 2
- Lung Diseases · Phase 2
- Lung Neoplasms · Phase 3
- Lymphoma · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Mesothelioma · Phase 2
- Microsatellite Instability · Phase 1/Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 3
- Neoplasms, Germ Cell and Embryonal · Phase 1/Phase 2
- Oropharyngeal Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1/Phase 2
- Papillomaviridae · Phase 2
- Penile Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Sarcoma · Phase 2
- Sarcoma, Kaposi · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Thymoma · Phase 2
- Thymus Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Urogenital Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 2
- Vaginal Neoplasms · Phase 2
- Vulvar Neoplasms · Phase 1/Phase 2
Mechanism of action
- Transforming growth factor betaBINDING AGENT
Transforming growth factor beta binding agent
- Programmed cell death 1 ligand 1BINDING AGENT
Programmed cell death 1 ligand 1 binding agent
- Transforming growth factor beta-1INHIBITOR
TGFB1 inhibitor
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298024 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05445882 | Phase 2 | Dec 29, 2022 | National Cancer Institute (NCI) |
| NCT05145569 | Phase 1 | Dec 31, 2021 | Case Western Reserve University, Merck, University of Pittsburgh |
| NCT05012098 | Phase 2 | Dec 7, 2021 | National Cancer Institute (NCI) |
| NCT04874311 | Phase 2 | Nov 1, 2021 | Institut Bergonié, Merck KGaA |
| NCT04708470 | Phase 1/Phase 2 (Phase 2) | Oct 5, 2021 | National Cancer Institute (NCI) |
| NCT05061823 | Phase 3 | Sep 25, 2021 | Merck KGaA, Merck Serono |
| NCT05005429 | Phase 2 | Sep 20, 2021 | Fundación GECP |
| NCT04708067 | Phase 1 | Aug 31, 2021 | University of Texas at Houston |
| NCT04727541 | Phase 2 | Jul 8, 2021 | AIO-Studien-gGmbH, J. W. Goethe University, Merck Serono |
| NCT04971187 | Phase 2 | Jun 30, 2021 | University of Texas at Houston |
| NCT04878250 | Phase 2 | Jun 30, 2021 | University of London |
| NCT04835896 | Phase 1/Phase 2 (Phase 2) | May 1, 2021 | Yonsei University |
| NCT04756505 | Phase 1 | Mar 7, 2021 | University of Texas at Houston |
| NCT04789668 | Phase 1/Phase 2 (Phase 2) | Jan 15, 2021 | University of Texas at Houston |
| NCT04648826 | Phase 1/Phase 2 (Phase 2) | Jan 8, 2021 | National Cancer Institute (NCI) |
| NCT04633252 | Phase 1/Phase 2 (Phase 2) | Jan 8, 2021 | National Cancer Institute (NCI) |
| NCT04595149 | Phase 2 | Nov 30, 2020 | University of Amsterdam |
| NCT04574583 | Phase 1/Phase 2 (Phase 2) | Nov 24, 2020 | National Cancer Institute (NCI) |
| NCT04501094 | Phase 2 | Oct 26, 2020 | National Cancer Institute (NCI) |
| NCT04551950 | Phase 1 | Oct 19, 2020 | Merck KGaA, Merck Serono |
Showing 20 of 54 trials
Page 1 / 3
Organizations
Research & Development (36)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 23 | 20 | 2 | 2018 |
| Merck KGaA | For profit | 16 | 0 | 3 | 2018 |
| Merck Serono | For profit | 15 | 10 | 3 | 2018 |
| University of Texas at Houston | Academic/Hospital | 10 | 10 | 2 | 2018 |
| The University of Hong Kong | Academic/Hospital | 2 | 2 | 1 | 2020 |
| University of Amsterdam | Academic/Hospital | 2 | 2 | 2 | 2020 |
| AIO-Studien-gGmbH | For profit | 1 | 1 | 1 | 2021 |
| Austin Health | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Curie Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Deventer Ziekenhuis | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Elisabeth-TweeSteden Ziekenhuis | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Fundación GECP | Academic/Hospital | 1 | 1 | 1 | 2021 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2020 |
| Institut Bergonié | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Isala Clinics, Zwolle, The Netherlands | Academic/Hospital | 1 | 0 | 1 | 2020 |
| J. W. Goethe University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Maastricht University | Academic/Hospital | 1 | 0 | 1 | 2020 |
36 organizations
Page 1 / 2